TRX
NEUTRALTissue Regenix Grants Share Options to CEO and EMEA Director
The regenerative medical devices company has granted restricted share units to its CEO and conditional share awards to its EMEA Business Director.
Tissue Regenix Group
36.50GBX
-1.35%
Market Cap
26.00M
Volume
15.12k
22% of avg
P/E Ratio
0.47
EPS (TTM)
0.77
Beta
0.92
Day Range
35.00p - 37.00p
52 Week Range
25.00p36.50p67.00p
36.50p
Upcoming Events
5 December 2024
Threshold for major shareholding change crossed
High Impact Event
TRX
NEUTRALTissue Regenix Announces Posting of Annual Report and Notice of AGM
The medical technology company has announced the posting of its annual report and notice of upcoming AGM.
TRX
NEUTRALTissue Regenix Reports Record EBITDA Despite Market Headwinds
The regenerative medicine company reported record adjusted EBITDA profitability and 9% revenue growth, despite facing headwinds in certain markets. However, cash position decreased and overall losses continue.
TRX
NEUTRALTissue Regenix Receives CE and UKCA Certification for OrthoPure® XT
The regenerative medical device company has received CE and UKCA certification for its OrthoPure® XT product, allowing continued access to European and UK markets.
TRX
NEUTRALTissue Regenix Concludes Strategic Review, Focuses on Standalone Growth
The regenerative medical devices company has concluded its strategic review without a sale, and will now focus on delivering growth as an independent business.
TRX
NEUTRALTissue Regenix Granted European Patent for Decellularisation Technology
The medical technology company has been granted a European patent for its innovative decellularisation technology, further protecting its intellectual property.
TRX
NEUTRALTissue Regenix Provides Company Update
The medical technology company provides a general update on its business, indicating it continues to execute on its strategy as it looks to drive further growth in 2025.
TRX
GOODTissue Regenix Reports Continued Growth and Profitability in FY24 Trading Update
The regenerative medical devices company reported 8% revenue growth and expects to exceed profit expectations for the full year, marking a second consecutive year of profitability. However, the strategic review of a German joint venture introduces some uncertainty.
TRX
NEUTRALLexham Special Opportunities I LP Increases Stake in Tissue Regenix
Tissue Regenix, a medical technology company, sees a change in its shareholder structure.
TRX
NEUTRALTissue Regenix Sees Increase in Institutional Investor Holding
Medical technology company Tissue Regenix sees increase in institutional investor holding, but limited information provided on current performance.